Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 19% Improvement Relative Risk Improvement 74% Time to improvement 29% Hospitalization time 31% c19early.org/d Sarhan et al. NCT04738760 Vitamin D RCT LATE TREATMENT Favors high dose Favors low dose
Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial
27 Sep 2022    Source   PDF   Share   Tweet
RCT comparing 200,000IU IM cholecalciferol and 1mcg/day alfacalcidol, showing lower mortality and improved recovery with high dose treatment.
risk of death, 18.5% lower, RR 0.81, p = 0.003, treatment 26 of 58 (44.8%), control 30 of 58 (51.7%), NNT 14, adjusted per study, odds ratio converted to relative risk, multivariable.
improvement, 74.4% better, OR 0.26, p = 0.03, treatment 58, control 58, adjusted per study, inverted to make OR<1 favor treatment, multivariable, RR approximated with OR.
time to improvement, 28.8% lower, relative time 0.71, p = 0.002, treatment 58, control 58.
hospitalization time, 31.5% lower, relative time 0.69, p = 0.04, treatment 58, control 58.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sarhan et al., 27 Sep 2022, Randomized Controlled Trial, Egypt, peer-reviewed, 9 authors, study period December 2020 - June 2021, dosage 200,000IU single dose, trial NCT04738760 (history).
Contact: gomaa@ju.edu.sa (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit